The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients
Open accessAbstract
Anti-angiotensin II type 1 receptor (AT1R) antibodies have been associated with allograft rejection. We hypothesized that circulating AT1R antibodies might identify kidney transplant recipients at increased risk of allograft rejection and loss who are not identified by the HLA system. We prospectively enrolled 1845 kidney transplant recipients from two centers. Donor-specific HLA antibodies (DSAs) and AT1R antibodies were measured at the time of the first acute rejection episode or at 1 year post-transplant. Allograft biopsy was performed to evaluate the rejection phenotype and to assess for endothelial activation. Overall, 371 (20.1%) participants had AT1R antibodies, 334 (18.1%) had DSAs, and 133 (7.2%) had both. AT1R antibodies were associated with an increased risk of allograft loss (adjusted HR 1.49, 95% CI 1.07-2.06 for AT1R antibodies alone and 2.26, 95% CI 1.52-3.36 for AT1R antibodies and DSAs). Participants with AT1R antibodies had a higher incidence of antibody-mediated rejection (AMR) compared with participants without AT1R antibodies (25.0% vs. 12.9%). Among 77 participants with histological features of AMR but without DSAs, 51 (66.2%) had AT1R antibodies. Compared to participants with prototypical DSA-mediated rejection, those with AT1R antibody-associated rejection had a higher prevalence of hypertension, more vascular rejection with arterial inflammation, higher levels of endothelial-associated transcripts, and lack of complement deposition in allograft capillaries. Thus, AT1R antibodies may identify kidney transplant recipients at high risk of allograft rejection and loss, independent of the HLA system. Recognition of complement-independent AT1R antibody-mediated vascular rejection could lead to the development of new treatment strategies to improve allograft survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rejection of the Kidney Allograft
Nankivell, B. J., & Alexander, S. I. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0902927 · Cited by 605
Cited by
Loupy, A., Haas, M., Roufosse, C., Naesens, M., Adam, B., Afrouzian, M., Akalin, E., Alachkar, N., Bagnasco, S., Becker, J. U., et al. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15898 · Cited by 834
Self-citationNaesens, M., Roufosse, C., Haas, M., Lefaucheur, C., Mannon, R. B., Adam, B. A., Aubert, O., Böhmig, G. A., Callemeyn, J., Clahsen-van Groningen, M., et al. (2024) · American Journal of Transplantation · doi:10.1016/j.ajt.2023.10.016 · Cited by 310
Self-citationAllorecognition and the spectrum of kidney transplant rejection
Callemeyn, J., Lamarthée, B., Koenig, A., Koshy, P., Thaunat, O., & Naesens, M. (2022) · Kidney International · doi:10.1016/j.kint.2021.11.029 · Cited by 189
Metadata
- Authors
- Lefaucheur, C., Viglietti, D., Bouatou, Y., Philippe, A., Pievani, D., Aubert, O., Duong Van Huyen, J.-P., Taupin, J.-L., Glotz, D., Legendre, C., Loupy, A., Halloran, P. F., & Dragun, D.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 96
- Issue
- 1
- Pages
- 189-201
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W2922198755
- Cited by
- 161
- References
- 1
- FWCI
- 22.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. https://app.cochat.ai/papers/10.1016/j.kint.2019.01.030
- The paper
- Lefaucheur, C., Viglietti, D., Bouatou, Y., Philippe, A., Pievani, D., Aubert, O., Duong Van Huyen, J.-P., Taupin, J.-L., Glotz, D., Legendre, C., Loupy, A., Halloran, P. F., & Dragun, D. (2019). Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. Kidney International. https://doi.org/10.1016/j.kint.2019.01.030
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.